Business

Shionogi to develop coronavirus vaccine, with trials eyed for this year

KYODO

Shionogi & Co. said Monday it will develop a vaccine for the novel coronavirus with the aim of starting clinical trials this year.

The Osaka-based company has decided to develop a recombinant protein vaccine through its subsidiary UMN Pharma Inc. while also seeking to discover therapeutic drugs for the disease. Shionogi said it is looking to offer the vaccine for 10 million people.

The company is coordinating its plans with relevant parties, including the Health, Labor and Welfare Ministry.

Your news needs your support

Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.

Coronavirus banner